Bendamustine-based Combination Therapy for PCNSL
Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: Chonnam National University Hospital
Listed as NCT03392714, this PHASE2 trial focuses on PCNSL and remains ongoing. Sponsored by Chonnam National University Hospital, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chonnam National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .